HAE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Haemonetics Corp (HAE) is not a strong buy for a beginner investor with a long-term focus at this moment. While the company has shown positive financial trends in net income, EPS, and gross margin, the recent revenue decline and mixed analyst sentiment suggest caution. Additionally, the technical indicators and options data do not strongly support a compelling entry point currently.
The MACD is positive and expanding, indicating bullish momentum. However, RSI is neutral at 62.685, and moving averages are converging, suggesting no clear trend. The stock is trading near its pivot level of 59.918, with resistance at 62.764 and support at 57.072.
Haemonetics recently received FDA 510(k) clearance for its NexSys PCS Plasma Collection System with Persona PLUS technology, which could enhance plasma collection efficiency and drive future growth. The company also reported strong YoY increases in net income (19.33%) and EPS (28.38%) in Q3 2026.
Revenue declined by 2.75% YoY in Q3 2026, which raises concerns about growth sustainability. Analyst ratings and price targets have been mixed, with some firms lowering their targets. Additionally, there are no significant hedge fund or insider trading trends to indicate strong confidence in the stock.
In Q3 2026, revenue dropped by 2.75% YoY to $338.97M. However, net income increased by 19.33% YoY to $44.74M, EPS rose by 28.38% YoY to 0.95, and gross margin improved by 6.77% to 56.47%.
Analyst sentiment is mixed. While firms like Barrington and Baird raised price targets to $94 and $81 respectively and maintained Outperform ratings, others like Citi and Mizuho lowered targets to $75 and $80. The consensus reflects cautious optimism but lacks strong conviction.
